Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Isis Earns $10M Biogen Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Isis Earns $10M Biogen Milestone

Initiates IND-enabling studies for ISIS-BIIB3Rx

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $10 million milestone payment from Biogen Idec for the initiation of studies to support an IND for ISIS-BIIB3Rx, a development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
 
ISIS-BIIB3Rx is the third drug Isis is developing with Biogen. Isis is eligible to receive as much as $215 million in additional milestone payments and license fees. Should Biogen exercise its option to exclusively license ISIS-BIIB3Rx, Isis is eligible to receive royalties on sales of ISIS-BIIB3Rx. 
 
“Our collaboration with Biogen Idec has been productive and has allowed us to significantly expand the application of our technology to discover and develop drugs to treat patients with neurological diseases. We now have three clinical programs from our partnership. As each of these programs advances, not only will we continue to earn additional milestone payments, but we will also continue to benefit from Biogen Idec’s active participation in these programs, lending their resources and expertise,” said C. Frank Bennett, Ph.D., senior vice president of research at Isis Pharmaceuticals.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics